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Abstract 
High dose nitrate (NO3-) supplementation via beetroot juice (BR, 1 mmol/kg/day) lowers mean 
arterial blood pressure (MAP) and improves skeletal muscle blood flow and O2 
delivery/utilization matching thereby raising microvascular O2 pressure (PO2mv). We tested the 
hypothesis that a low dose of NO3- supplementation, consistent with a diet containing NO3- rich 
vegetables (BRLD, 0.3 mmol/kg/day), would be sufficient to cause these effects.   Male Sprague-
Dawley rats were administered a low dose of NO3- (0.3 mmol/kg/day; n=12), a high dose (1 
mmol/kg/day; BRHD, n=6) or tap water (control, n=10) for 5 days. MAP, heart rate (HR), blood 
flow (radiolabeled microspheres) and vascular conductance (VC) were measured during 
submaximal treadmill exercise (20 m/min, 5% grade, equivalent to ~60% of maximal O2 uptake). 
Subsequently, PO2mv (phosphorescence quenching) was measured at rest and during 180 s of 
electrically-induced twitch contractions (1 Hz, ~6 volts) of the surgically-exposed spinotrapezius 
muscle. BRLD and BRHD lowered resting (control: 139±4, BRLD: 124±5, BRHD: 128±9 
mmHg, P<0.05) and exercising (control: 138±3, BRLD: 126±4, BRHD: 125±5 mmHg, P<0.05) 
MAP to a similar extent. For BRLD this effect occurred in the absence of altered exercising 
hindlimb muscle(s) blood flow or spinotrapezius PO2mv (rest and across the transient response at 
the onset of contractions, all P>0.05), each of which increased significantly for the BRHD 
condition (all P<0.05).  Whereas BRHD slowed the PO2mv kinetics significantly (i.e., >mean 
response time, MRT; control: 16.6±2.1, BRHD: 23.3±4.7 s) following the onset of contractions 
compared to control, in the BRLD group this effect did not reach statistical significance (BRLD: 
20.9±1.9 s, P=0.14). These data demonstrate that while low dose NO3- supplementation lowers 
MAP it does so in the absence of augmented muscle blood flow, VC and PO2mv; all of which are 
elevated at a higher dose. Thus, in healthy animals, a high dose of NO3- supplementation seems 
necessary to elicit significant changes in exercising skeletal muscle O2 delivery/utilization. 
 
 
Key words: nitric oxide; exercise; dietary nitrate; nitrite; mean arterial pressure; blood 
flow 
 
3 
 
1. Introduction 
A fundamental tenet of exercise physiology is that blood flow (BF) increases following 
exercise onset to meet the rising skeletal muscle energetic demands. This hyperemic response is 
mediated by a host of vasodilatory controllers (Joyner and Wilkins, 2007) and it is now widely 
accepted that nitric oxide (NO) plays a deterministic role in regulating not only O2 delivery 
(QO2) (Hirai et al. 1994; reviewed by Joyner and Tschakovsky, 2004), but also O2 utilization (
) within the skeletal muscle (Andrade et al. 1998; Larsen et al 2012). A growing body of 
evidence suggests that ingestion of inorganic nitrate (NO3-), for example via beetroot juice (BR), 
can, following a step-wise reduction, elevate NO bioavailability and thus impact skeletal muscle 
hemodynamic and metabolic function during exercise (Larsen et al. 2007; Bailey et al. 2009; 
Vanhatalo et al. 2010; Kenjale et al. 2011; Lansley et al. 2011a,b; Ferguson et al. 2013a,b).   
 In humans, NO3- supplementation via BR reduces blood pressure and enhances exercise 
tolerance in both healthy (Bailey et al. 2009; Vanhatalo et al. 2010; Lansley et al. 2011a,b; 
Cermak et al. 2012; Wylie et al. 2013b) and patient populations (i.e., peripheral arterial disease, 
Kenjale et al. 2011). These effects appear to have a dose-dependent response with no additional 
improvement in exercise tolerance after ingesting BR containing 16.8 compared to 8.4 mmol 
NO3- (Wylie et al. 2013a). The precise mechanisms for these improvements are not yet fully 
understood.  However, recent investigations using murine models implicate enhanced exercising 
muscle BF (i.e., ↑QO2, Ferguson et al. 2013a) and QO2/ matching (e.g. microvascular PO2; 
PO2mv, Ferguson et al. 2013b) combined with greater contractile efficiency (e.g.  ; 
Hernandez et al. 2012).   
VO2
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 Many disease states impair exercise tolerance and its restoration is a primary therapeutic 
goal. What is not known is whether lower doses of NO3- alter cardiovascular control and muscle 
oxygenation (i.e. PmvO2, which sets the pressure head for capillary-myocyte O2 flux) during 
exercise.  Specifically, one question of paramount ecological importance is whether NO3- dosing 
consistent with an individual eating a diet rich in leafy greens and other NO3- sources can 
achieve the cardiovascular and muscular benefits without the necessity for supplementation per 
se. Thus, we tested the hypotheses that a low dose of NO3- supplementation (i.e. consistent with a 
diet containing NO3- rich vegetables, 0.3 mmol/kg/day) would be sufficient to 1) raise plasma 
[NO3-] and [NO2-], 2) lower mean arterial pressure (MAP) at rest and during exercise, 3) elevate 
BF and vascular conductance (VC) in locomotory muscles of the hindlimb and 4) raise the 
PO2mv of the mixed fiber-type spinotrapezius muscle during the crucial rest-contractions 
transient. 
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Methods 
Animal selection and care   
Thirty-one young adult male Sprague-Dawley rats (~3-4 months of age, Charles River 
Laboratories, Wilmington, MA,USA) were used in this investigation.  Rats were maintained in 
accredited animal facilities at Kansas State University on a 12/12 hr light-dark cycle with food 
and water provided ad libitum.  All procedures were approved by the Institutional Animal Care 
and Use Committee of Kansas State University and conducted according to National Institutes of 
Health guidelines. All rats were familiarized with running on a custom-built motor-driven 
treadmill for 5 min/day at a speed of 20 m/min up a 5% grade for ~5 days.  
 
Supplementation protocol 
Rats were randomly assigned to receive 5 days of BR supplementation with either a low 
NO3- dose of 0.3 mmol/kg/day (BRLD; n=14), a higher NO3- dose of 1 mmol/kg/day (BRHD; 
n=6, Beet it™, James White Drinks, Ipswich UK) or untreated tap water (control; n=11) with 
consumption monitored. For both BRLD and BRHD rats, two days’ worth of BR was diluted in 
100 ml of tap water (average daily fluid consumption ~50-60 ml/day). This lower NO3- dose (0.3 
mmol/kg/day) represents a dose found in a diet containing NO3- rich vegetables, while the higher 
NO3- dose (1 mmol/kg/day) represents a dietary supplement with a NO3- concentration similar to 
that used by Jones and colleagues (Bailey et al. 2009; Vanhatalo et al.  2010; Lansley et al. 
2011a,b) after accounting for the resting metabolic rate of rats (~7x that of humans, Henson et al. 
1987; Musch et al. 1988). In an effort to minimize the unnecessary utilization of additional 
animals, both control and BRHD data presented herein represent a randomly selected subset of 
animals published recently.  The BRHD data represent a NO3- dose of 1 mmol/kg/day and 
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demonstrate a significant vascular effect of supplementation (Ferguson et al. 2013ab). Data from 
the BRLD group were obtained within the same time-frame as control and BRHD groups 
presented in Ferguson et al. (2013ab, e.g. within 16 weeks). In this way any potential seasonal 
differences or variations in rat-chow content were avoided.  
 
Surgical instrumentation 
Rats were anaesthetized with a 5% isoflurane-O2 mixture and maintained subsequently 
on 3% isoflurane-O2.  The carotid artery was isolated and cannulated with a catheter (PE-10 
connected to PE-50, Intra-Medic polyethylene tubing, Clay Adams Brand, Becton, Dickinson 
and Company, Sparks, MD) for the measurement of MAP and HR, infusion of the 
phosphorescent probe (see below), and arterial blood sampling.  A second catheter was placed in 
the caudal artery. The incisions were then closed and rats were given >1 hr to recover (Flaim et 
al. 1984). 
Protocol 1: Measurement of hindlimb skeletal muscle blood flow 
After recovery, rats were placed on the treadmill and the caudal artery catheter was 
connected to a 1 ml syringe chambered in a Harvard infusion/withdrawal pump (model 907, 
Cambridge, MA, USA). The carotid artery catheter was connected to a pressure transducer 
(Gould Statham P23ID, Valley View, OH, USA) maintained at the same height as the animal. 
Exercise was initiated and treadmill speed was increased progressively over a ~30 s period to a 
speed of 20 m/min (5% grade, ~60% O2 max; Musch et al. 1988). The rat continued to 
exercise for another 2.5 min until a total time of 3 min was reached. At 3 min the Harvard pump 
was activated and withdrawal was initiated at a rate of 0.25 ml · min-1. Simultaneously, HR and 
MAP were measured and recorded using the carotid artery catheter.  The carotid artery catheter 
VO2
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was then disconnected from the pressure transducer and 0.5-0.6 × 106 15 μm diameter 
radiolabeled microspheres (57Co or 85Sr in random order; Perkin Elmer, Waltham, MA, USA) 
were infused into the aortic arch for determination of regional BF. Following the microsphere 
infusion ~0.2 ml of blood was sampled from the carotid artery catheter for the determination of 
blood lactate concentration ([lactate]) (Nova Stat Profile M, Nova Biomedical, Waltham, MA, 
USA) after which exercise was terminated. 
 Following a minimum 1 hr recovery period, a second microsphere infusion (differently 
radio-labeled than the first) was performed while the rat sat quietly on the treadmill for the 
determination of resting BF, HR and MAP. This experimental strategy (i.e. exercise before rest) 
mitigates potential influences of the pre-exercise anticipatory response on resting skeletal muscle 
BF measurements (Armstrong et al. 1989).  
Protocol 2: Measurement of spinotrapezius muscle PO2mv 
Following the second (resting) microsphere infusion, rats were anesthetized progressively 
using diluted pentobarbital sodium anesthesia (administered into the caudal artery catheter to 
effect) with the level of anesthesia monitored continuously via the toe-pinch and blink reflexes.  
Rats were then placed on a heating pad to maintain core temperature at ~38 °C (measured via 
rectal probe).  Overlying skin and fascia were reflected carefully from the mid-dorsal caudal 
region of each rat and the right spinotrapezius muscle was carefully exposed in a manner that 
ensured the integrity of the neural and vascular supply to the muscle (Bailey et al. 2000).  Silver 
wire electrodes were sutured (6–0 silk) to the rostral (cathode) and caudal (anode) regions of the 
muscle.  The exposed spinotrapezius muscle was continuously superfused with a warmed (38°C) 
Krebs–Henseleit bicarbonate buffered solution equilibrated with 5% CO2–95% N2 and 
surrounding exposed tissue was covered with Saran wrap (Dow Brands, Indianapolis, IN).  The 
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spinotrapezius muscle was selected specifically based on its mixed muscle fiber-type 
composition and citrate synthase activity close to that found in human quadriceps muscle (Delp 
& Duan 1996; Leek et al. 2001). 
The phosphorescent probe palladium meso-tetra (4 carboxyphenyl)porphyrin dendrimer 
(R2: 15–20 mg·kg-1 dissolved in 0.4 ml saline) was infused via the carotid artery catheter.  After 
a brief stabilization period (~10 min), the common end of the light guide of a frequency domain 
phosphorometer (PMOD 5000, Oxygen Enterprises, Philadelphia, PA) was positioned ~2-4 mm 
superficial to the dorsal surface of the exposed right spinotrapezius muscle over a randomly 
selected muscle field absent of large vessels thus ensuring that the region contained principally 
capillary blood.  PO2mv was measured via phosphorescence quenching (see below) and reported 
at 2 s intervals throughout the duration of the 180 s contraction protocol (1 Hz, ~6 V, 2 ms pulse 
duration) elicited via a Grass stimulator (model S88, Quincy, MA).  Following the contraction 
period it was ensured that PmvO2 returned to baseline values (indicative of preserved vasomotor 
function). Rats were euthanized via pentobarbital sodium overdose (≥50 mg/kg administered into 
the carotid artery catheter).  
 
PO2mv measurement and curve-fitting 
The Stern-Volmer relationship allows the calculation of PO2mv through the direct 
measurement of a phosphorescence lifetime via the following equation (Rumsey et al., 1988): 
 
PO2mv = [(τ/ τ)-1]/(kQ x τ) 
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where kQ is the quenching constant and τ and τ are the phosphorescence lifetimes in the absence 
of O2 and the ambient O2 concentration, respectively.  For R2, kQ is 409 mmHg-1·s-1 and τ is 
601 µs (Lo et al., 1997) and these characteristics do not change over the physiological range of 
pH and temperature in the rat in vivo and, therefore, the phosphorescence lifetime is determined 
directly by the O2 pressure (Rumsey et al., 1988; Lo et al., 1997).   
The R2 phosphorescent probe binds to albumin, and consequently, is uniformly 
distributed throughout the plasma.  A previous study from our laboratory investigated 
systematically the compartmentalization of R2 and confirmed that it remains within the 
microvasculature of exposed muscle over the duration considered in the present experiments, 
thereby ensuring a valid PO2mv measurement (Poole et al., 2004).  
Curve-fitting of the measured PO2mv responses was performed with commercially 
available software (SigmaPlot 11.01, Systat Software, San Jose, CA) and the data were fit with 
either a one- or two-component model as described below: 
 
One component:  PO2mv (t) = PO2mv (BL) – Δ PO2mv (1 – e-(t - TD)/ τ) 
Two component:  PO2mv (t) = PO2mv (BL) – Δ1 PO2mv (1 – e-(t – TD1)/ τ1) + Δ2 PO2mv (1 – e-(t – TD2)/τ2) 
 
where PO2mv (t) represents the PO2mv at any given time t, PO2mv (BL) corresponds to the pre-
contracting resting baseline PO2mv, Δ1 and Δ2 are the amplitudes for the first and second 
components, respectively, TD1 and TD2 are the time delays for each component, and τ1 and τ2 are 
the time constants (i.e., time to 63% of the final response value) for each component.  Goodness 
of fit was determined using the following criteria: 1) the coefficient of determination, 2) sum of 
the squared residuals, and 3) visual inspection and analysis of the model fits to the data and the 
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residuals.  The mean response time (MRT) of the kinetics response was calculated for the first 
component in order to provide an index of the overall principal kinetics response according to 
the following equation: 
 
MRT1 = TD1 + τ1 
 
where TD1 and τ1 are as described above.  The delta of the initial PO2mv fall following 
contractions onset was normalized to τ1 (Δ1 PO2mv /τ1) to provide an index of the relative rate of 
fall.  Additionally, the time taken to reach 63% of the initial PO2mv fall was determined 
independently from the modeling procedures (T63) to ensure appropriateness of the model fits.  
Specifically, the raw PO2mv data were interpolated, and the time coinciding with 63% of the 
total amplitude (Δtotal PO2mv) was determined. 
 
Determination of BF and VC 
Following euthanasia, the thorax of each rat was opened and placement of the carotid 
artery catheter was confirmed before the internal organs and individual muscles and muscle parts 
of the hindlimb were identified and excised. Upon removal, tissues were weighed and placed 
promptly into counting vials. Radioactivity of each tissue was determined with a gamma 
scintillation counter (Packard Auto Gamma Spectrometer, model 5230, Downers Grove, IL, 
USA). Tissue BF was then calculated using the reference sample method (Musch & Terrell, 
1992) and expressed as ml/min/100 g. Adequate mixing of the microspheres was verified for 
each microsphere infusion as demonstrated by a <15% difference in BF to the right and left 
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kidneys and to the right and left hindlimb musculature. VC was calculated by normalizing BF to 
MAP and expressed as ml/min/100 g · ∙mmHg-1.  
 
Blood sampling and measurement of plasma [NO3-] and [NO2-] 
Post-supplementation blood samples were collected following surgical instrumentation 
via the caudal artery catheter to assess 1) plasma [NO3-] and [NO2-] and 2) pH, PO2, and %O2 
saturation. For plasma [NO3-] and [NO2-], ~0.8 ml of blood was drawn into heparinized tubes and 
rapidly centrifuged at 6000 g at 4°C for 6 minutes. Plasma was then extracted and frozen 
immediately at -80°C for later analysis. A second ~0.3 ml blood sample was drawn and analyzed 
for pH, PO2, and %O2 saturation (Nova Stat Profile M, Nova Biomedical, Waltham, MA, USA). 
All measurements of plasma NO3- and NO2- were performed within 30 minutes of 
thawing via chemiluminescence with an Ionic/Sievers NO analyzer (NOA 280i, Sievers 
Instruments, Boulder, CO, USA). In order to obtain plasma NO2- levels and to avoid potential 
reduction of NO3-, potassium iodide in acetic acid was used as a reductant. This reductant 
possesses the ability to reduce NO2- to NO but is incapable of reducing higher oxides of nitrogen 
(i.e. NO3-) thus increasing the specificity for NO2-. Plasma NO3- concentrations were then 
obtained using the same apparatus with the stronger reductant vanadium chloride in hydrochloric 
acid at a temperature of 95°C. This stronger reductant reduces the sum of all nitrogen oxides 
with an oxidation state of +2 or higher (predominantly NO3- [µM]) but also includes NO2- and 
nitrosothiols [nM].  Consequently, the signals obtained using potassium iodide were subtracted 
from those with vanadium chloride to provide a clearer representation of the NO3- 
concentrations. 
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Statistical analysis 
 Data are presented as mean ± standard error of the mean (SEM).  Results were compared 
within (rest vs. exercise) and between (control vs. BRLD vs. BRHD) using mixed 2-way analysis 
of variance (ANOVA) with Student-Newman-Keuls post hoc tests where appropriate. 
Significance was accepted at P<0.05. 
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Results 
 There were no between-group differences in the total hind-limb muscle/body mass ratio 
(control: 4.4 ± 0.1, BRLD: 4.3 ± 0.1, BRHD: 4.2 ± 0.2%, P>0.05).  BRHD, but not BRLD, rats 
had significantly higher plasma [NO3-] and [NO2-] when compared to control (Figure 1).  
 
Protocol 1: BF and VC at rest and during exercise 
MAP and HR. MAP at rest was reduced in BRLD rats compared to control. However, 
despite >10 mmHg lower average, resting MAP was not significantly different in BRHD rats 
when compared to control (P=0.20, Figure 2). During treadmill exercise MAP was reduced for 
both BRLD and BRHD groups when compared to control (Figure 2).  Neither HR at rest 
(control: 408 ± 8, BRLD: 408 ± 17, BRHD: 407 ± 18 beats/min, P>0.05) or during exercise 
(control: 528 ± 10, BRLD: 508 ± 14, BRHD: 525 ± 7 beats/min, P>0.05) was altered for BRLD 
or BRHD. 
 
 Blood gases, blood [lactate], hematocrit. There were no between-group differences in 
arterial PO2, PCO2, or hematocrit at rest or during exercise (data not shown, P>0.05 for all). 
Resting and exercising arterial blood [lactate] were not different among groups (Table 1, P>0.05 
for all) but tended (P=0.12) to be lower for BRHD during exercise.  
 
 BF and VC. There were no differences in resting total hindlimb skeletal muscle BF 
(control: 16 ± 2, BRLD: 19 ± 2, BRHD: 21 ± 5 ml/min/100g, P>0.05) or VC (control: 0.12 ± 
0.01, BRLD: 0.15 ± 0.02, BRHD: 0.16 ± 0.03 ml/min/100g/mmHg, P>0.05) between groups. 
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Similarly, there were no differences in resting BF or VC in any of the 28 individual hindlimb 
muscles or muscle parts (Table 1).  
Total exercising hindlimb muscle BF and VC were greater in BRHD rats when compared 
to BRLD and control rats (Figure 3). Specifically, BRHD supplemented rats had greater BF in 
15, and VC in 20, of the 28 individual hindlimb muscles and muscle parts (Table 2) when 
compared to control and BRLD rats. There were no between-group differences in BF or VC at 
rest or during exercise to organs of the splanchnic region (Table 3).  
 
Protocol 2: PO2mv parameters 
 Representative raw PO2mv profiles of control, BRLD and BRHD rats are presented in 
Figure 4. The responses were fit by a one-component model in 2 of 11 control, 6 of 12 BRLD 
and 2 of 5 BRHD rats while the more complex two-component model was utilized for the 
remainder. The r2 (control: 0.99 ± 0.01, BRLD: 0.98 ± 0.01, BRHD: 0.98 ± 0.01) and low sum of 
squared residuals (control: 20.2 ± 3.1, BRLD: 18.3 ± 2.7, BRHD: 21.1 ± 7 mmHg) for both 
groups supported that the model fits were suitable. Table 4 presents the average PO2mv baselines 
and kinetics parameters. There were no differences in the PO2mv (BL) between groups. However, 
following the onset of contractions BRHD, but not BRLD, demonstrated a longer TD1, smaller 
first-component amplitude and slower PO2mv kinetics (i.e., longer MRT1). Overall (i.e., PO2mv 
(BL) minus PO2mv (steady-state), ΔtotalPO2mv) amplitudes tended to be less in BRHD (P=0.06) but 
failed to reach statistical significance. There were no differences in PO2mv (steady-state) during 
contractions between groups. 
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4. Discussion 
The principal original finding of this investigation is that low dose NO3- supplementation 
via beetroot juice (0.3 mmol/kg/day, BRLD), at levels consistent with a diet rich in leafy green 
vegetables consumed by humans, lowers resting and exercising MAP.  Moreover, this occurred 
in the absence of increased exercising skeletal muscle BF and VC which are both elevated after 
higher supplementation doses (1 mmol/kg/day, BRHD). That BRLD impacts cardiovascular 
control at levels that do not detectably increase circulating NO3- or NO2- suggests that central 
mechanisms of cardiovascular control, possibly within the rostral ventrolateral medulla (RVLM) 
region of the brain, are extremely sensitive to altered dietary NO3- intake.  Given that, in humans, 
reductions in systolic blood pressure of ~10 mmHg (as seen with BRLD herein) have been 
estimated to decrease the risk of stroke by ~35% and ischemic heart disease by ~25% 
(MacMahon et al. 1990; Lewington et al. 2002; Law et al. 2003; Lawes et al. 2003; Larsen et al. 
2007,2010), these findings have strong potential clinical significance.  It is also pertinent that 
employing low dose inorganic NO3- supplementation may avoid or reduce the opportunity for 
development of NO3- tolerance and endothelial dysfunction (Vanhatalo et al. 2010; Omar et al. 
2012) which occur especially after chronic administration of organic NO3- (see Wylie et al. 
2013a for discussion). 
Relationship to existing literature 
The randomly selected subset of data from results initially reported from our laboratory 
(Ferguson et al. 2013a) demonstrate clearly the effects of BRHD as regards elevated skeletal 
muscle(s) BF and VC and reduced MAP during treadmill running. Also, as demonstrated in 
Figure 4, PO2mv kinetics were slowed significantly and PO2mv decreased less during 
contractions of the spinotrapezius muscle, effectively raising the microvascular O2 driving 
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pressure especially across the transition period when mitochondrial O2 uptake would be rising 
most rapidly (Ferguson et al. 2013b).  These effects can be explained by the greater O2 delivery 
combined with a reduced mitochondrial O2 utilization at a given workload as demonstrated in 
intact humans (Larsen et al. 2007; Bailey et al. 2009; Larsen et al. 2010; Wylie et al. 2013a) as 
well as in isolated mitochondria (Larsen et al. 2012).  With respect to the BRLD and based upon 
the dose-response relationship reported by Wylie et al. (2013a), where a graded fall in MAP was 
observed from 4.2 to 8.4 mmol NO3- (supplemented via BR with no additional decrease at 16.8 
mmol), we were surprised that, in rats, MAP fell to the same extent (i.e., ~10 mmHg) with both 
doses.  Paramount to setting the NO3- supplement doses herein was the consideration of the faster 
metabolic rate found in the resting rat (~27 ml/kg/min, Musch et al. 1988) when compared to 
humans (3.5ml/kg/min, i.e. ~7-8 fold higher per unit mass, Henson et al. 1987).  Taking this into 
account, the doses employed (i.e., BRLD, 0.3; BRHD, 1 mmol/kg/day) correspond broadly to 3.2 
and 7.4 mmol/day, respectively in humans.  Thus, with respect to species differences, the NO3- 
derived hypotensive response becomes saturated at lower doses in rats than in their human 
counterparts.  This effect is very different from the skeletal muscle vascular response and that of 
PO2mv which are manifested only at the higher dose.  
Mechanisms for reduction of mean arterial pressure 
The increased VC observed in the skeletal muscle(s) of BRHD rats explain, at least in 
part, the reduction in MAP found at the higher dose. However, in marked contrast, skeletal 
muscle VC and BF were unchanged for BRLD (which was not unexpected given that circulating 
NO3-/NO2- levels were not different from control values) and thus, the reduced MAP for these 
animals must have a different explanation.  There is evidence that NO bioavailability (from both 
endothelial and neuronal nitric oxide synthase, eNOS and nNOS) in higher cardiovascular neural 
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control centers, for example the RVLM, impacts sympathetic outflow and controls, or at least 
influences, MAP regulation and can lead to a reduction and/or redistribution of cardiac output 
(e.g. Mayorov, 2005; Gao et al. 2008). Although not measured in this investigation, it is possible 
that BRLD may have altered NO bioavailability in the RVLM. Indeed, elevated NO 
bioavailability via overexpression of eNOS in the RVLM induces significant hypotension by 
elevating gamma-aminobutyric acid (GABA) production (Kishi et al. 2001).  Thus, one putative 
mechanism for the hypotensive response invoked by BRLD relates to increased NO 
bioavailability in the RVLM from non-nNOS/eNOS dependent sources which may ultimately 
reduce sympathetic outflow.  A greater NO3- dose may intensify this effect which could be 
responsible, at least in part, for the elevated renal BF and VC seen in BRHD rats herein. 
Furthermore, the presence of antioxidants in the BR supplement may contribute to this effect 
(Gao et al. 2007) and thus play a synergistic role with NO3-. This novel aspect of BR and NO3- 
mediated cardiovascular control carries clinical implications for those suffering from renal 
vascular diseases (Lundberg et al. 2008; Carlstöm et al. 2011) and warrants future investigation. 
Alternative mechanisms of BR induced reductions in MAP include impacts on other 
vascular beds, apart from the skeletal muscle vasculature. For example, BRHD rats demonstrated 
26% greater renal BF at rest (Table 3) suggesting that the renal circulation may be prone to NO2- 
induced vascular effects. Given that resting renal BF was not significantly elevated in BRLD 
rats, this particular effect may require greater local concentrations of NO2- to elicit significant 
vascular effects within the renal circulation. While not statistically significant, a mild impact of 
the renal circulation on the resting MAP of BRLD rats is certainly plausible and should be 
investigated further. What’s more, the lower PO2 environment of the venous circulation may 
enhance the reduction of circulating NO2- to NO and other reactive nitrogen species, which 
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would likely cause venodilation and a reduction in MAP. This effect would likely be exacerbated 
during exercise due to the robust reductions in venous blood PO2 (to values <30 mmHg, 
Gonzalez et al. 1994) offering a partial explanation for the lower exercising MAP values 
presented in figure 2. 
Experimental considerations 
The rat is a widely used and valuable experimental model to study cardiovascular and 
muscle metabolic control particularly during exercise.  Moreover, dietary, pharmaceutical and 
exercise conditions can be well controlled and standardized within this population.  However, 
determination of “equivalent” NO3- doses is challenging and basing such on resting metabolic 
rate differences found between rats and humans is only a first approximation. Importantly, in the 
BRHD group plasma [NO3-] and [NO2-] were raised to levels approximating those seen in 
humans following consumption of a dietary supplement high in NO3- (Lundberg & Govoni, 
2004; Kenjale et al. 2011) providing additional confidence in the doses used herein. What is 
particularly exciting with respect to the present results is that BRLD represented a dose that 
evinced clear cardiovascular responses in the absence of a significant increase in plasma NO3- or 
NO2- and the vascular and metabolic consequences of such.  This observation unveils a novel, 
potentially exciting, and heretofore unappreciated consequence of BR-derived NO3- 
supplementation. 
Conclusions 
This investigation was the first to examine the effects of a low (0.3 mmol/kg/day) and 
high (1 mmol/kg/day) dose of NO3- supplementation on vascular responses at rest and during 
submaximal locomotory exercise in the rat. Despite the absence of elevations of plasma [NO3-] 
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or [NO2-], BRLD evoked reductions in MAP at rest and during exercise. These cardiovascular 
improvements were further amplified in BRHD rats which demonstrated augmented skeletal 
muscle BF and VC, which likely resulted in the slowed PO2mv fall during the crucial rest-
contraction transition presented herein. These results carry tremendous clinical implications 
particularly for those at risk for stroke, renal, and ischemic heart diseases (MacMahon et al. 
1990; Lewington et al. 2002; Law et al. 2003; Lawes et al. 2003; Larsen et al. 2007, 2010; 
Tsuchiya et al. 2010; CarlstrÖm et al. 2011). Given the sensitivity of the RVLM to NO 
bioavailability (Mayorov, 2005; Gao et al. 2008), it seems logical to postulate an interaction 
between NO3-, NO2- and central cardiovascular control centers located in the brain (i.e. RVLM). 
Understanding these interactions will further provide a mechanistic linkage between elevated 
NO3- ingestion and the improved cardiovascular and metabolic function seen in humans (Bailey 
et al. 2009, 2010; Larsen et al. 2010; Kenjale et al. 2011; Vanhatalo et al. 2011; Masschelein et 
al.2012; Wylie et al. 2013b) and animals (Ferguson et al. 2013a,b; Hernandez et al. 2013) and 
thus should be the focus of future investigations.  
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Table 1. Effects of low dose and high dose BR supplementation on resting hindlimb muscle BF (ml/min/100g) and 
VC (ml/min/100g/mmHg). 
 
 
         BF           VC 
 Control BRLD BRHD  Control BRLD BRHD 
Ankle extensors        
Soleus (9%)   87 ± 16 119 ± 17 107 ± 33  0.62 ± 0.11 0.96 ± 0.12 0.79 ± 0.24 
Plantaris (80%) 15 ± 2 16 ± 2 9 ± 2  0.11 ± 0.01 0.13 ± 0.01 0.07 ± 0.02 
Gastrocnemius, red (14%) 43 ± 7 56 ± 9 58 ± 19  3.07 ± 0.05 0.44 ± 0.07 0.43 ± 0.13 
Gastrocnemius, white (100%) 14 ± 2 12 ± 2 10 ± 3  0.10 ± 0.05 0.10 ± 0.02 0.08 ± 0.02 
Gastrocnemius, mixed (91%) 14 ± 2 16 ± 2 16 ± 4  0.10 ± 0.02 0.12 ± 0.02 0.12 ± 0.02 
Tibialis posterior (73%) 17 ± 2 18 ± 3 16 ± 5  0.12 ± 0.01 0.14 ± 0.02 0.12 ± 0.03 
Flexor digitorum longus (68%) 19 ± 2 24 ± 2 10 ± 2  0.15 ± 0.02 0.19 ± 0.02 0.08 ± 0.01 
Flexor halicus longus (71%) 13 ± 2 12 ± 2 9 ± 2  0.09 ± 0.01 0.09 ± 0.01 0.07 ± 0.01 
        
Ankle flexors        
Tibialis anterior, red (63%) 19 ± 3 27 ± 7 21 ± 10  0.14 ± 0.02 0.21 ± 0.06 0.15 ± 0.07 
Tibialis anterior, white (80%) 20 ± 2 18 ± 3 16 ± 4  0.14 ± 0.02 0.15 ± 0.02 0.12 ± 0.03 
Extensor digitorum longus (76%) 16 ± 2 15 ± 2 15 ± 4  0.12 ± 0.01 0.12 ± 0.01 0.11 ± 0.03 
Peroneals (67%) 17 ± 3 15 ± 2 19 ± 4  0.12 ± 0.02 0.12 ± 0.02 0.14 ± 0.03 
        
Knee extensors        
Vastus intermedius (4%) 46 ± 9 84 ± 18 93 ± 48  0.32 ± 0.06 0.66 ± 0.13 0.69 ± 0.35 
Vastus medialis (82%) 15 ± 2 17 ± 3 25 ± 9  0.10 ± 0.01 0.13 ± 0.02 0.19 ± 0.06 
Vastus lateralis, red (35%) 40 ± 6 66 ± 16 83 ± 31  0.28 ± 0.04 0.19 ± 0.04 0.61 ± 0.22 
Vastus lateralis, white (100%) 16 ± 2 14 ± 2 13 ± 3  0.11 ± 0.01 0.11 ± 0.02 0.10 ± 0.02 
Vastus lateralis, mixed (89%) 16 ± 1 21 ± 4 29 ± 9  0.12 ± 0.01 0.17 ± 0.04 0.21 ± 0.06 
Rectus femoris, red (66%) 23 ± 4 24 ± 4 29 ± 14  0.16 ± 0.03 0.19 ± 0.04 0.20 ± 0.10 
Rectus femoris, white (100%) 15 ± 2 16 ± 3 17 ± 5  0.11 ± 0.01 0.13 ± 0.02 0.12 ± 0.03 
        
Knee flexors        
Biceps femoris anterior (100%) 11 ± 1 9 ± 1 10 ± 2  0.07 ± 0.01 0.07 ± 0.01 0.08 ± 0.01 
Biceps femoris posterior (92%) 11 ± 2 12 ± 2 15 ± 3  0.08 ± 0.01 0.10 ± 0.01 0.11 ± 0.02 
Semitendinosus (83%) 12 ± 2 14 ± 2 18 ± 5  0.08 ± 0.01 0.11 ± 0.02 0.14 ± 0.03 
Semimembranosus, red (72%) 15 ± 2 19 ± 3 28 ± 9  0.11 ± 0.02 0.15 ± 0.02 0.21 ± 0.06 
Semimembranosus, white (100%) 13 ± 2 11 ± 1 12 ± 2  0.09 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 
        
Thigh adductors        
Adductor longus (5%) 115 ± 7 142 ± 12 148 ± 12  0.84 ± 0.06 1.12 ± 0.10 1.19 ± 0.12 
Adductor magnus & brevis (89%) 15 ± 3 16 ± 3 23 ± 7  0.11 ± 0.02 0.13 ± 0.02 0.17 ± 0.05 
Gracilis (77%) 16 ± 3 17 ± 2 20 ± 4  0.11 ± 0.02 0.13 ± 0.01 0.15 ± 0.03 
Pectineus (69%) 17 ± 2 23 ± 4 28 ± 7  0.12 ± 0.01 0.19 ± 0.03 0.21 ± 0.04 
        
Data are mean ± SEM. Values in parentheses indicate % type IIb + d/x according to Delp & Duan (1996). 
Control; n=10, BRLD; n=14, BRHD; n=6. 
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Table 2. Effects of low dose and high dose BR supplementation on exercising hindlimb muscle BF 
(ml/min/100g) and VC (ml/min/100g/mmHg). 
          BF           VC 
 Control BRLD BRHD  Control BRLD BRHD 
Ankle extensors        
Soleus (9%) 297 ± 46 251 ± 19 328 ± 39  2.15 ± 0.33 2.04 ± 0.20 2.60 ± 0.26 
Plantaris (80%) 208 ± 17 194 ± 18 249 ± 10  1.51 ± 0.11 1.56 ± 0.17 2.00 ± 0.06* 
Gastrocnemius, red (14%) 444 ± 48 391 ± 40 507 ± 42  3.21 ± 0.32 3.13 ± 0.28 4.07 ± 0.31* 
Gastrocnemius, white (100%) 44 ± 7 42 ± 8 71 ± 14*  0.31 ± 0.05 0.32 ± 0.05 0.56 ± 0.10* 
Gastrocnemius, mixed (91%) 153 ± 13 135 ± 12 214 ± 19*  1.11 ± 0.08 1.08 ± 0.10 1.71 ± 0.11* 
Tibialis posterior (73%) 121 ± 18 111 ± 11 137 ± 22  0.88 ± 0.13 0.89 ± 0.09 1.10 ± 0.18 
Flexor digitorum longus (68%) 103 ± 15 113 ± 19 106 ± 19  0.74 ± 0.10 0.92 ± 0.17 0.84 ± 0.15 
Flexor halicus longus (71%) 74 ± 11 69 ± 11 88 ± 11  0.53 ± 0.07 0.55 ± 0.08 0.70 ± 0.07 
        
Ankle flexors        
Tibialis anterior, red (63%) 347 ± 38 303 ± 22 388 ± 35  2.50 ± 0.26 2.38 ± 0.16 3.08 ± 0.19 
Tibialis anterior, white (80%) 120 ± 15 109 ± 11 170 ± 24*  0.86 ± 0.10 0.86 ± 0.08 1.34 ± 0.16* 
Extensor digitorum longus (76%) 57 ± 8 60 ± 6 83 ± 13*  0.46 ± 0.05 0.47 ± 0.04 0.66 ± 0.09* 
Peroneals (67%) 129 ± 13 123 ± 10 172 ± 8*  0.93 ± 0.09 0.98 ± 0.08 1.38 ± 0.05* 
        
Knee extensors        
Vastus intermedius (4%) 371 ± 41 320 ± 28 358 ± 54  2.68 ± 0.29 2.54 ± 0.23 2.88 ± 0.41 
Vastus medialis (82%) 122 ± 18 111 ± 13 185 ± 36  0.88 ± 0.12 0.87 ± 0.10 1.48 ± 0.28* 
Vastus lateralis, red (35%) 393 ± 47 327 ± 29 486 ± 48  2.84 ± 0.32 2.60 ± 0.23 3.91 ± 0.39* 
Vastus lateralis, white (100%) 32 ± 5 33 ± 5 51 ± 10*  0.23 ± 0.03 0.26 ± 0.04 0.40 ± 0.07* 
Vastus lateralis, mixed (89%) 169 ± 23 151 ± 14 243 ± 17*  1.23 ± 0.16 1.20 ± 0.11 1.95 ± 0.13* 
Rectus femoris, red (66%) 233 ± 35 245 ± 15 33 ± 37*  1.69 ± 0.24 1.95 ± 0.13 2.64 ± 0.30* 
Rectus femoris, white (100%) 103 ± 14 94 ± 8 197 ± 38*  0.74 ± 0.09 0.75 ± 0.06 1.55 ± 0.27* 
        
Knee flexors        
Biceps femoris anterior (100%) 49 ± 9 50 ± 7 77 ± 16*  0.36 ± 0.06 0.40 ± 0.05 0.63 ± 0.13* 
Biceps femoris posterior (92%) 79 ± 9 81 ± 9 135 ± 13  0.57 ± 0.07 0.65 ± 0.07 1.09 ± 0.10* 
Semitendinosus (83%) 57 ± 7 51 ± 5 80 ± 13*  0.41 ± 0.05 0.40 ± 0.04 0.63 ± 0.11* 
Semimembranosus, red (72%) 120 ± 16 116 ± 10 172 ± 17*  0.87 ± 0.11 0.93 ± 0.10 1.38 ± 0.13* 
Semimembranosus, white (100%) 34 ± 6 32 ± 4 67 ± 14*  0.25 ± 0.04 0.25 ± 0.03 0.54 ± 0.11* 
        
Thigh adductors        
Adductor longus (5%) 321 ± 42 268 ± 20 333 ± 51  2.32 ± 0.29 2.17 ± 0.20 2.66 ± 0.40 
Adductor magnus & brevis (89%) 82 ± 9 71 ± 7 116 ± 19*  0.59 ± 0.06 0.60 ± 0.06 0.93 ± 0.14* 
Gracilis (77%) 42 ± 5 41 ± 6 60 ± 11  0.30 ± 0.03 0.33 ± 0.06 0.48 ± 0.08* 
Pectineus (69%) 49 ± 7 59 ± 8 84 ± 17*  0.35 ± 0.05 0.46 ± 0.06 0.68 ± 0.14* 
        
Data are mean ± SEM. Values in parentheses indicate  % type IIb + d/x according to Delp & Duan (1996). 
Control; n=10, BRLD; n=14 BRHD; n=6. *P<0.05 vs. control. P<0.05 vs. BRLD. 
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Table 3.  Effects of low dose and high dose BR supplementation on kidney and splanchnic region 
organ BF (ml/min/100g) and VC (ml/min/100g/mmHg) at rest and during exercise. 
          Rest          Exercise 
 Control BRLD BRHD  Control BRLD BRHD 
BF        
Kidney 414 ± 29 447 ± 32  521 ± 32*  421 ± 47 372 ± 35 436 ± 52† 
Stomach 82 ± 8 94 ± 13  71 ± 16   68 ± 15 51 ± 6† 49 ± 9 
Adrenals 557 ± 91 601 ± 57  667 ± 67  349 ± 79 321 ± 49 594 ± 188 
Spleen 345 ± 54 332 ± 37  501 ± 134  63 ± 16† 81 ± 14† 99 ± 33† 
Pancreas 117 ± 11 112 ± 14  86 ± 15  115 ± 15 103 ± 10 116 ± 28 
Sm. Intestine 304 ± 17  361 ± 38 269 ± 38  247 ± 30 238 ± 21† 255 ± 53 
Lg. Intestine 131 ± 13 153 ± 18   139 ± 18  135 ± 15 126 ± 13 142 ± 21 
Liver** 37 ± 13 32 ± 6 40 ± 8  17 ± 4 18 ± 2 41 ± 11 
        
VC        
Kidney 3.04 ± 0.27 3.65 ± 0.32 4.15 ± 0.27*  3.04 ± 0.31 3.13 ± 0.43 3.51 ± 0.44 
Stomach 0.59 ± 0.06 0.75 ± 0.10 0.54 ± 0.09  0.50 ± 0.11 0.41 ± 0.05† 0.39 ± 0.07 
Adrenals 4.06 ± 0.72 4.71 ± 0.37 5.42 ± 0.80  2.86 ± 0.49 2.51 ± 0.37† 4.79 ± 1.57 
Spleen 2.50 ± 0.40 2.63 ± 0.27 3.71 ± 0.85  0.45 ± 0.11† 0.64 ± 0.28† 0.79 ± 0.28 
Pancreas 0.85 ± 0.08 0.88 ± 0.11 0.65 ± 0.09  0.83 ± 0.11 0.83 ± 0.08 0.92 ± 0.23† 
Sm. Intestine 2.18 ± 0.14 2.87 ± 0.28 2.06 ± 0.25  1.72 ± 0.20 1.89 ± 0.17† 2.00 ± 0.43 
Lg. Intestine 0.95 ± 0.10 1.21 ± 0.14 1.09 ± 0.11  0.98 ± 0.10 1.00 ± 0.10 1.13 ± 0.16 
Liver** 0.26 ± 0.12 0.21 ± 0.04 0.26 ± 0.05  0.12 ± 0.03 0.15 ± 0.02 0.32 ± 0.08 
        
        
Data are mean ± SEM. *, P< 0.05 vs. Control. †, P < 0.05 vs. rest. **Indicates arterial, not portal, BF 
and VC. 
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Table 4. Microvascular partial pressure of O2 (PO2mv) kinetics parameters at rest and during 
contractions for control, BRLD and BRHD rats. 
 Control BRLD BRHD 
PO2mv (BL) (mmHg) 31.1 ± 2.0 30.1 ± 1.9 26.4 ± 2.8
∆1PO2mv (mmHg) 16.7 ± 1.5 12.9 ± 0.7* 11.8 ± 0.9*
∆2PO2mv (mmHg) 3.9 ± 0.8 3.6 ± .3 3.8 ± 0.4
∆totalPO2mv (mmHg) 13.6 ± 1.6 11.1 ± 1 9.6 ± 1.5
PO2mv (steady-state)(mmHg) 18 ± 1.7 19 ± 1.4 17.7 ± 2.0
TD1 (s) 6.7 ± 1.5 8.6 ± 0.9 12.9 ± 2.8*
TD2 (s) 49.8 ± 11.2 54 ± 15.6 27 ± 5.5
τ1 (s) 9.9 ± 1.2 8.6 ± 0.9 10.4 ± 2.2
τ2 (s) 89.4 ± 18.7 93.9 ± 21.2 86.1 ± 10.9
MRT1 (s) 16.6 ± 2.1 20.9 ± 1.9 23.3 ± 4.7*
∆1PO2mv/ τ1 (mmHg/s) 1.9 ± 0.3 1.3 ± 0.2 1.4 ± 0.3 
 
Values are mean ± SEM. Where second component model averages are shown the value reflects 
only those rats where a two-component model was applied to describe the PO2mv data (control: 
n=9, BRLD: n=6, BRHD: n=3). PmvO2(BL), pre-contraction PO2mv; ∆1PO2mv, amplitude of the 
first component; ∆2PO2mv, amplitude of the second component; ∆totalPO2mv, overall amplitude 
regardless of one- or two-component model fit; PO2mv (steady-state), PO2mv during contracting 
steady-state; TD1, time delay for the first component; TD2, time delay for the second component; 
τ1, time constant for the first component; τ2, time constant for the second component; MRT1, 
mean response time describing the overall kinetics response; ∆1PO2mv/ τ1, parameter describing 
the relative rate of PO2mv fall. 
*P<0.05 vs. control. 
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Figure captions 
 
Figure 1.  Top panel: Post-supplementation plasma [NO3-] for control, BRLD and BRHD rats.  
Bottom panel: Post-supplementation plasma [NO2-] for control, BRLD and BR rats.  *P<0.05 
versus control #P<0.05 versus BRLD. 
 
Figure 2. Resting and exercising mean arterial pressures for control, BRLD and BRHD rats. 
*P<0.05 versus control. 
 
Figure 3. Total hindlimb BF and VC for control, BRLD and BRHD rats during submaximal 
locomotory exercise. *P<0.05 versus control. 
 
Figure 4. Raw representative PO2mv profiles for control, BRLD and BRHD rats during 180 s of 
1-Hz twitch contractions.   
  
30 
 
Figure 1. 
*
*
Pl
as
m
a 
[N
O
3-
 ] 
( M
)
0
50
100
150
200
* #
Pl
as
m
a 
[N
O
2-
 ] 
(n
M
)
0
200
400
600
800 *#
Control BRLD BRHD  
31 
 
Figure 2. 
 
Rest Exercise
M
AP
 (m
m
H
g)
0
110
115
120
125
130
135
140
145
Control
BRLD 
BRHD
* * 
* 
32 
 
Figure 3. 
B
F 
(m
l/m
in
/1
00
g)
0
100
110
120
130
140
150
160
170
180
*
VC
 (m
l/m
in
/1
00
g/
m
m
H
g)
0.00
0.25
0.50
0.75
1.00
1.25
1.50
Control BRLD BRHD
*
 
33 
 
Figure 4. 
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